Browse by author
Lookup NU author(s): Dr Ethan SenORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2019 Elsevier Inc. Juvenile idiopathic arthritis (JIA) is the commonest rheumatic disease in children and JIA-associated uveitis its most frequent extra-articular manifestation. The uveitis is potentially sight-threatening and so carries a considerable risk of morbidity. The commonest form of uveitis seen in JIA is chronic anterior uveitis which is almost always asymptomatic in the initial stages. Therefore, screening for JIA-associated uveitis in at-risk patients is essential. The aim of early detection and treatment is to minimise intra-ocular inflammation and avoid complications leading to visual loss, resulting from both disease activity and medications. There is increasing evidence for the early introduction of systemic immunosuppressive therapies in order to reduce topical and systemic glucocorticoid use. Two randomised controlled trials of adalimumab in JIA-associated uveitis provide convincing evidence for the use of this biologic in patients who fail to respond adequately to methotrexate. Tocilizumab and baricitinib are being investigated as alternatives to anti-tumour necrosis factor drugs.
Author(s): Sen ES, Ramanan AV
Publication type: Review
Publication status: Published
Journal: Clinical Immunology
Year: 2020
Volume: 211
Print publication date: 01/02/2020
Online publication date: 09/12/2019
Acceptance date: 05/12/2019
ISSN (print): 1521-6616
ISSN (electronic): 1521-7035
Publisher: Academic Press Inc.
URL: https://doi.org/10.1016/j.clim.2019.108322
DOI: 10.1016/j.clim.2019.108322
PubMed id: 31830532
